for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alpine Immune Sciences Inc

ALPN.OQ

Latest Trade

13.23USD

Change

1.16(+9.61%)

Volume

35,231

Today's Range

12.31

 - 

13.33

52 Week Range

7.96

 - 

16.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.07
Open
12.31
Volume
35,231
3M AVG Volume
1.95
Today's High
13.33
Today's Low
12.31
52 Week High
16.29
52 Week Low
7.96
Shares Out (MIL)
29.22
Market Cap (MIL)
352.69
Forward P/E
-6.61
Dividend (Yield %)
--

Next Event

Q4 2021 Alpine Immune Sciences Inc Earnings Release

Latest Developments

More

Alpine Immune Sciences Posts Q3 Loss Per Share Of $0.55

Alpine Immune Sciences Posts Qtrly Loss Per Share $0.46

Alpine Immune Sciences Files For Mixed Shelf Of Upto $150 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alpine Immune Sciences Inc

Alpine Immune Sciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

Industry

Business Services

Contact Info

188 East Blaine St., Suite 200

SEATTLE, WA

98102

United States

+1.206.7884545

https://www.alpineimmunesciences.com/

Executive Leadership

Mitchell H. Gold

Executive Chairman of the Board, Chief Executive Officer

Stanford L. Peng

President, Head of Research and Development

Paul Rickey

Chief Financial Officer, Senior Vice President, Corporate Secretary

Jay R. Venkatesan

Director

Robert E. Conway

Independent Director

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.630

2019

-2.280

2020

-1.340

2021(E)

-1.730
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.36
Price To Book (MRQ)
2.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.44
LT Debt To Equity (MRQ)
3.70
Return on Investment (TTM)
-28.85
Return on Equity (TTM)
-21.42

Latest News

Latest News

BRIEF-Alpine Immune Sciences Inc Files For Mixed Shelf Of Up To $60 Mln

* ALPINE IMMUNE SCIENCES INC FILES FOR MIXED SHELF OF UP TO $60 MILLION - SEC FILING Source text: [https://bit.ly/2AGhcqG] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Alpine Immune Sciences Says Anticipate Having Enough Cash To Fund Planned Operations Into 2023

* ALPINE IMMUNE SCIENCES - ANTICIPATES HAVING ENOUGH CASH TO FUND PLANNED OPERATIONS INTO 2023, EXCLUDING REVENUE FROM EXISTING PARTNERSHIPS OR NEW ARRANGEMENTS

BRIEF-Alpine Immune Sciences And Abbvie Announce Option And License Agreement For Development And Commercialization Of ALPN-101

* ALPINE IMMUNE SCIENCES AND ABBVIE ANNOUNCE OPTION AND LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALPN-101

BRIEF-Alpine Reports Qtrly Loss Per Share Of $0.30

* ALPINE IMMUNE SCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Alpine Immune Sciences Says Q4 Loss Per Share Of $0.33

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Alpine Immune Sciences’ Alpn-101 Receives FDA Orphan Drug Designations For The Prevention And Treatment Of Acute Graft Versus Host Disease

* ALPINE IMMUNE SCIENCES’ ALPN-101 RECEIVES FDA ORPHAN DRUG DESIGNATIONS FOR THE PREVENTION AND TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up